New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
07:17 EDTMASI, BCR, CFN, COVCovidien looking to make acquisitions, NY Times says
Medical device maker Covidien plans to use a portion of its free cash flow for strategic acquisitions in the near-term, the company's CEO said, The New York Times reported yesterday.. Reference Link
News For COV;BCR;MASI;CFN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 12, 2015
19:37 EDTBCRC.R. Bard reports outcomes from Lutonix registry study
C. R. Bard announced the presentation of 12-month results from the Lutonix Global Real-World Registry at the Transcatheter Cardiovascular Therapeutics 2015 meeting. In the registry study, the Lutonix 035 drug coated balloon demonstrated a freedom from target lesion revascularization rate of 94.3% in femoropopliteal arteries at 12 months in 631 patients and, based upon interim data from 170 early enrolled patients, a freedom from TLR rate of 93% at 24 months.
October 8, 2015
08:05 EDTMASIMasimo study says PVI to help clinicians assess fluid responsiveness
Masimo announced that an 18-study meta-analysis of 665 subjects reported that Masimo's Pleth Variability Index, available with Masimo's SET and rainbow SET monitoring platforms, may help clinicians assess fluid responsiveness in mechanically ventilated patients in normal sinus rhythm in the operating room and intensive care unit. The meta-analysis, published in the Journal of Clinical Monitoring and Computing by Dr. Chu and colleagues from The First Hospital of China Medical University, Shenyang, China, combined the findings from 18 independent studies evaluating the ability of PVI to help clinicians assess fluid responsiveness.
October 2, 2015
06:02 EDTBCRAcacia Research enter into settlement and patent license with C.R. Bard
Subscribe for More Information
September 30, 2015
08:43 EDTBCRC.R. Bard to acquire full ownership of JV in Japan
C.R. Bard announced it has entered into a definitive agreement to acquire Kobayashi Pharmaceutical Co's 50% ownership share in Medicon, the Osaka, Japan-based joint venture that the two companies have operated together since 1972, through a share redemption. The transaction is expected to close in early November 2015, after which Medicon will be a wholly-owned subsidiary of the company. The transaction has been approved by each company's board of directors and is subject to customary closing conditions. The company expects the transaction to add approximately $40M to 2016 net sales. On an operational basis, the company expects the transaction to be neutral to adjusted cash earnings per share both in the fourth quarter of 2015 and the full-year 2016, and to be accretive thereafter. Including the impact of foreign exchange, the company expects the transaction to reduce fourth quarter 2015 and full year 2016 adjusted cash earnings per share by approximately 5c and 20c, respectively. As consideration for the transaction, Kobayashi will receive JPY3B at closing. Kobayashi will also receive the following additional payments annually on the anniversary date of the transaction: JPY1.9B in 2016, JPY1.5B in 2017, JPY1.2B in 2018, JPY1B in 2019, JPY600M in both 2020 and 2021, JPY400M in both 2022 and 2023, and JPY300M in both 2024 and 2025; the total consideration being JPY11.2B.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use